Introduction
Malaria continues to exert a heavy disease and death burden, despite being preventable and treatable [1] . While parasite-based diagnosis of malaria is increasing, most suspected cases are treated following presumptive diagnosis, resulting in unnecessary over-use of antimalarial drugs for non-malaria febrile illness, and an inability to effectively track true malaria morbidity [2] .
In 2006, WHO issued its first Guidelines for the Treatment of Malaria [3] . Since then, most countries where Plasmodium (P.) falciparum is endemic have progressively updated treatment policies to shift from failing chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) to the WHO-recommended artemisinin-based combination therapies (ACTs). In its second edition [4] of the Guidelines in 2010, WHO additionally?recommended parasitological confirmation by microscopy or RDT for all patients suspected of malaria, including children under-5 years, before starting treatment; treatment solely on the basis of clinical suspicion is to be considered only when a parasitological diagnosis is not accessible [4] .
The roll-out of RDTs will greatly enhance the quality of malaria diagnosis and treatment in many high-endemic areas, and will decrease over-use of ACTs in patients with non-malarial fevers, as demonstrated in studies undertaken in Senegal and Tanzania [5, 6] . Improved diagnostic coverage with RDTs should also improve malaria surveillance.
As with other health innovations, a range of contextual and health system factors [6±10] as well as clinical and health service readiness are likely to influence the adoption of the new case management guidelines. Although the proportion of suspected cases in Africa who received a malaria diagnostic test has risen from 20% in 2005 to 45% in 2010, RDT coverage remains low [1] , and many malaria-affected countries especially in Africa continue the outdated, harmful practice of presumptively treating fever cases as malaria [1,11±13] .
Microscopy remains the reference method for malaria diagnosis, but many endemic and non-endemic countries lack expertise in microscopy [2, 14] . Malaria RDTs were introduced in the 1990s [14] . Since then, more than 60 RDT brands and over 200 different products have been developed [15] , with improving sensitivity and specificity. Since the publication of WHO's 2006 Guidelines, many countries have begun to expand RDT usage. However, the extent of this expansion is not known, as routine health information systems do not always distinguish between microscopy and RDT use.
The Global Fund to fight AIDS, Tuberculosis and Malaria (Global Fund) began investing in malaria control in 2002. By 2010 Global Fund investments accounted for around 75% of global external funding for malaria [16] , complementing financing by the United States President's Malaria Initiative (PMI), which, since 2005, has been a significant donor for malaria control programs in 19 countries in Africa and the Greater Mekong sub-region in Asia. These external investments have provided recipient countries the opportunity to accelerate the adoption of recommended malaria case management policies. We analyzed Global Fund investments across 81 countries with malaria grants for the period 2005 to 2010 to ascertain uptake of RDTs, and health service readiness for their deployment.
Methods

Program Data Source and Collection
We used data from Global Fund-supported malaria programs (Box S1) covering the period 2005 to 2010 for, (i) Country Procurement and Supply Management (PSM) plans by country and grant that identify the quantities of RDTs to be procured; (ii) Price and Quality Reporting (PQR) system, which includes data reported by Global Fund recipients on health products procured including RDTs and ACTs (http://www.theglobalfund.org/en/ procurement/pqr/); (iii) Grant indicator results related to RDTs, extracted from Performance Frameworks of each grant, namely RDTs distributed, RDTs used, RDTs used or microscope tests performed (from grants that reported RDT and microscopy results as one overall combined number; Table 1 ), health facilities equipped with RDTs, and personnel trained to perform RDTs; (iv) Financial data on the amounts budgeted in grants for malaria diagnosis.
As grants use different indicators are used to report RDTrelated activities to the Global Fund [17] , the reported results are individually checked and aligned to the calendar years when the results are actually reported.
Malaria Epidemiology Data
We obtained global and country-specific epidemiological data for malaria from WHO World Malaria Reports from 2006 to 2010. We used malaria endemicity categorization proposed in the World Malaria Report 2008 [18] to group countries as low or high endemicity, defined as below or equal and above 50 malaria cases per 1,000 population.
Data Analysis
We used PSM plan data aggregated by year and geographic regions, and grouped by year. PQR-reported RDT and ACT procurements were tabulated and the ratio of volumes of RDTs to treatment courses calculated. Both the totals and the ratio are reported as results. We aggregated program implementation results by year, geographic region and malaria endemicity. Regional analysis stratified data according to Global Fund regions [19] , into Africa (East Africa and Indian Ocean, Southern Africa, West and Central Africa, Middle East and North Africa), Asia (East Asia and the Pacific, South and West Asia); and the rest of world (Eastern Europe and Central Asia, Latin America and Caribbean). Analysis was done using SPSS 13.0 (SPSS Inc., Chicago, IL).
Results
196 malaria grants in 81 countries had secured funding from the Global Fund through Rounds 1 to 9. By 2010, the Global Fund had committed US$5.3 billion to malaria programs in these countries. In 2010, 5.2% of the budgets of these grants were allocated to diagnosis, including RDTs [19] .
Over 2005 to 2010, 96 malaria grants in the 81 countries had procurement plans that included an RDT component; 62 grants in 52 countries reported actual RDT procurement data into the PQR in 2009 or 2010; 87 grants from 76 countries reported program implementation results for malaria diagnosis. 
PSM Plans and PQR Data
Program Implementation Results
Cumulatively, 61.1 million RDTs were distributed from 2005 to 2010 through Global Fund-supported malaria programs ( Table 1) . The majority of RDTs were distributed in Africa (51.3 million, 83.9%) and in countries of high malaria endemicity (48.6 million i. e. 79.5%) ( Tables 2 and 3) .
RDT distributions increased from 971,900 in 2006 to 19.2 million in 2010 (Table 1 ). In 2009, RDT distributions equalled PQR-reported RDT procurements (16.4 million), suggesting rapid distribution of RDTs after procurement. In 2010, RDT distributions were close to 80% the volume of RDT procurements (19.2 million and 24.5 million respectively) ( Table 1) .
From 2005 to 2010, 114.7 million parasitological tests were reportedly done, including 17.7 million`RDTs tests' alone and an additional 97.0 million`RDTs tests or microscope slides' as a combined indicator. About half of these tests (55.5 million; 50.1%) were reported by countries in Africa, close to half (47.9 million; 49.4%) by Asian countries (Table 2) , and 63.8% (62.9 million) by countries of low malaria endemicity ( Table 3) .
The number of RDTs used increased substantially, from 
Discussion
The analysis shows a substantial increase in availability and use of RDTs in Global Fund supported malaria programs including RDTs procured and distributed, number of tests performed, and health service readiness to undertake diagnostic tests using RDTs. Adoption of a complex health innovation involves series of changes in behavior and practice [20] . Making resources available to procure RDTs is only the first step. An efficient delivery system is vital to distribute diagnostic kits to users and ensure their timely use within the shelf life. Effective RDT usage is also influenced by the readiness of health facilities, staff trained in RDT use and regular supply of RDTs, especially during the high transmission seasons, together with ACTs and other essential drugs to treat non-malaria febrile cases. Health personnel should be well trained to perform RDTs, interpret results, and prescribe treatment accordingly. Besides sustained training and capacity building, RDTs procured n/a n/a n/a n/ Although impressive, the observed increase in number of RDTs procured still falls short of estimated need. The Roll Back Malaria Partnership [16] estimated a global annual need of 1.6 billion suspected malaria cases requiring diagnosis in 2010 alone ± assuming that all fever cases in all endemic countries would seek care. To cover 50% of these fever cases, 800 million RDTs would have been needed in 2010 alone to confirm or exclude malaria, well above the 24.5 million RDTs procured or 48.97 million RDT kits planned procurements in Global Fund-supported programs in 2010. The other major external funder of malaria programs globally, PMI, had procured 25.1 million RDTs cumulatively by 2010 [22] , bringing the total externally financed RDT purchases to just below 50 million in 2010± much lower than the estimated global need.
We found low ratios of RDT procurements to ACT procurements in programs supported by both the Global Fund and the PMI. In 2010, Global Fund recipients procured one RDT per 2.94 ACTs (24.5 million RDTs versus 72.1 million ACTs), and PMI one RDT per 3.07 ACTs (13.3 million RDTs versus 41.0 million ACTs). Although still low, these ratios have increased from 2009, when they were one RDT per 3.9 ACTs for Global Fund, and one RDT per 3.5 ACTs for PMI. In line with relatively low RDT procurement, only 5% of the budget of Global Fund malaria grants was allocated to malaria diagnosis in 2010. Similarly, in malaria programs supported by the PMI, diagnosis covered only 7.5% of budgets during fiscal year 2011 [23] .
These results indicate that there is room to improve budget allocation in Global Fund ±supported malaria programs, optimizing the effectiveness and value for money in case management, by more balanced allocations and priority scale-up for parasitological diagnosis, especially in the highest-endemic African countries. Between 2002 and 2010, the Global Fund financed proposals based on country demand. This has generally resulted in an equitable distribution of grant disbursements by disease burden, but not necessarily optimized allocations among interventions within each disease program. The Global Fund's 2012±2016 Strategy`Investing for impact', recent revisions in country eligibility and prioritization criteria, and refined requirements for counterpart financing to disease programs by all supported governments now facilitate better targeting of Global Fund funding to essential highest-impact interventions and to countries with the highest continuing need [24] . In June 2012, the Global Fund became signatory to WHO's`Test Treat Track initiative [25] . As a consequence, all malaria grants that include case management activities must now include a pragmatic and realistic approach to diagnostic scale-up to be approved.
The analysis is not without limitations. One limitation is the completeness of grant-reported data. Regarding program implementation, indicators included in grant performance frameworks reflect only selected activities with large budgets that contribute critically to the objectives and goals of the proposal. RDT services delivered are not always fully reported by all programs receiving RDT support, so that the programmatic results presented must be considered minimum estimates. Similarly, PQR reporting of RDT procurements is probably not complete across all grants and programs, as reporting is enforced only at the time that a grant completes its Periodic Review after 2 years of grant implementation. Our exclusion of some price outliers from the PQR-based analysis contributes further to the procurement figures representing a lower-bound estimate. For microscopy-based diagnosis, indicator data on microscopes procured, health facilities equipped with microscopes and health workers trained to use microscopes are at present not systematically aggregated in the Global Fund's portfolio-level data system, because of known limitations in completeness and comparability among grants. Reporting on the indicator`RDTs and microscopy slides read' certainly does not cover the majority of microscopybased diagnoses delivered in programs whose grants did not support RDT roll-out. For these reasons, the data presented cannot be used to quantify the flow from RDT procurements to distribution and usage, or the balance between tests used and personnel trained.
Moreover, the analysis presents numerical results on the extent of Global Fund support to the adoption of 2006 and 2010 WHO Malaria Treatment Guidelines, but it does not systematically compare these results with the corresponding need to realize universal diagnostic access, such as population at risk, demand in terms of suspected malaria or fever cases, health staff requiring training or health facilities to be equipped.
Despite these limitations, the present analysis is the first, most comprehensive systematic triangulation of Global Fund support to rolling-out RDT-based diagnosis through all stages in the chain of an innovative policy implementation. As the Global Fund transitions to a new model of financing health programs based on`informed demand' that prioritizes proven highest-impact interventions, and strategic programming or re-programming to replace the more`passive disbursement' that characterized the period 2000±2009 [24] , investments in RDTs should increase. Increased RDT investments are critical to realize the RBM and WHO target of universal coverage of parasitological diagnosis before treatment initiation and to achieve the global goal of reducing malaria deaths to near-zero by 2015 [26] .
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